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on naïve and exposed populations was available for colistin and colistin-P, respec-
tively. ConClusions: By conducting an alternative approach where the naïve and 
exposed arms were considered separate treatment-by-population groups, the full 
evidence base could be evaluated, including the data for the dry-powder colis-
timethate sodium inhaler. This will provide relevant information to support clinical 
decision making in CF.
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objeCtives: To gather data on clinical effectiveness of lacosamide add-on ther-
apy to standard antiepileptic drugs (AEDs) in the Czech Republic. These data were 
intended as inputs for a cost-effectiveness analysis. Methods: A retrospective 
multicenter (n= 40) data collection of patients with epilepsy treated with lacosamide 
for 6 months in clinical practice was performed. Information on the number of sei-
zures and concomitant AEDs before and after lacosamide treatment was observed. 
In this analysis patients reporting at least a 50% reduction in seizure number 3 
months after lacosamide treatment were considered responders. Adverse events 
reported after initiating lacosamide treatment were collected. Results: In total, 
data from 409 patients were collected, 403 had complete data that were analyzed. 
Mean (SD) age was 40.4 (±14.2) years and the mean (SD) time since diagnosis 18.7 
(±12.8) years. In 91% of patients lacosamide treatment was initiated because of 
resistance to previous AEDs. Most patients suffered from partial (44.2%), second-
ary generalized (20.1%) or both (34.0%) types of seizures, or other (1.7%). Following 
lacosamide administration the mean (median) number of seizures decreased from 
baseline of 40.3 (12.0) to 25.9 (7.0) (per 3 months). Median (mean) number of sei-
zure reduction was equal to 41% (30%), and 45% were responders. Adverse events 
occurred in 79 pts (19.6%), with somnolence (6.2%) and dizziness (5.5%) most fre-
quently reported. During lacosamide administration, a decrease in concomitant 
AEDs number was observed. The mean number per patient decreased from 2.2 to 
1.7, as did concomitant AEDs used before and after lacosamide administration: 
levetiracetam (39% vs. 33%), lamotrigine (38% vs. 32%), carbamazepine (34% vs. 
29%), valproate (33% vs. 28%) and zonisamide (17% vs. 8%). ConClusions: Results 
confirm the effectiveness of lacosamide in the reduction of seizure frequency in 
clinical practice. In addition, findings suggest that adding lacosamide may lead to 
a reduced use of other concomitant AEDs.
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objeCtives: To analyse the cost of different anti-migraine products to determine 
price differences and the impact of generic prescribing. Methods: A retrospective 
drug utilisation study was conducted on South African medical insurance claims 
data for 2011. No clinical information was available. Results: A total of 797 patients 
received 1583 anti-migraine products during 2011. The majority of patients (70.14%) 
were females and 47.05% of patients were between 30 and 49 years old. Only 13.96% 
of patients claimed their anti-migraine products from the chronic plan of their 
medical insurance schemes. The average age of patients was 41.61 (SD= 14.91) years, 
with females on average slightly older than males (41.89 years vs. 40.96 years). 
Clonidine was the most frequently prescribed active ingredient (accounting for 
49.21% of the number of prescriptions, yet only for 25.70% of the amount claimed for 
anti-migraine products). Triptans (selective serotonin (5-HT1B/1D)-receptor agonists) 
accounted for 27.98% of all anti-migraine prescriptions, but accounted for 45.92% 
of cost. Five different triptans were prescribed. The average cost per sumatriptan 
prescription was the lowest (R177.64) of all the triptans. Sumatriptan was the only 
triptan with generic equivalents. Rizatriptan was the most often prescribed triptan, 
accounting for 18.51% of prescribing frequency and 29.15% of the amount claimed. 
Tablets and wafers were the preferred dosage forms. Only 0.32% of prescriptions 
were for triptan nasal sprays and they were on average the most expensive dos-
age form prescribed (R428.82 per prescription). ConClusions: The results of this 
study were in agreement with the findings of previous South African studies. The 
cost saving implications of generic prescribing were clear in this study. Migraine is 
an expensive condition to treat and is also affecting the economically active sec-
tor of the population. Studies investigating the economic impact of migraine will 
therefore yield valuable results.
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objeCtives: Despite the lack of evidence-based efficacy of cerebroprotective drugs, 
one-third of Europe’s population uses of these drugs (WHO statistics). The pur-
pose of the study - to research the dynamics of cerebroprotectors consumption in 
Ukraine. Methods: Determination of cerebroprotectors consumption by means of 
frequency analysis, ATC/DDD-methodology during 6 months in 2012 in Ukraine. The 
consumption of cerebroprotective drugs in money term does not give a true picture 
about the volume of pharmacotherapy using these drugs, that is why ATC/DDD-
methodology was used. As a unit of consumption DDD and PDD were used. Results: 
A comparison of outpatient and inpatient cerebroprotective drugs consumption 
during 6 months in a neurological hospital and in a drugstore in Kharkov, it was 
found, that 58 trade names (TN) of drugs in the amount of $ 28218 (the rate of $ 1: 
8,16 UAH on 1.10.12), in the hospital 17 TNs were used in the amount of $1518. It is 
shown, that the inpatient consumption of cerebroprotectors is much higher, than 
outpatient consumption, for example, vincamine - 2,32 DDDs/100 patients and 1,66 
DDDs/100 bed–days; piracetam - 2,59 DDDs /100 patients and 0, 15 DDDs/100 bed-
objeCtives: To assess the effects of early psychosocial intervention on delaying the 
institutionalization of patients with mild Alzheimer’s disease (AD) and on caregiv-
ers’ health-related quality of life (HRQOL). Methods: Totally, 240 patient-caregiver 
dyads were recruited to a pragmatic, controlled, and randomized (1:2) clinical trial 
in 3 hospital districts in Finland between 2002-2006. A primary outcome measure 
was the intervention’s impact on cumulative risk of institutionalization over 36 
months of follow up. In the analysis of the primary outcome, Fine & Gray’s (1999) 
proportional subhazards (sHR) model was applied to adjust the impact of compet-
ing risk (i.e., death). Main secondary outcome measures were caregivers’ global 
burden (measured by Global Health Questionnaire GHQ) and HRQOL measured by 
the 15D. The secondary outcomes were analyzed using generalized linear mixed 
models (GLMM) with hierarchical structure to account for repeated measures and 
possible clustering by the hospital district. Results: After 36 months of follow 
up, cumulative competing risk adjusted incidence of institutionalization rates 
(95% CI) were 21.2% (12.5% – 29.9%) and 16.1% (10.3% - 21.9%) in the intervention 
and usual care groups, respectively. Age and sex adjusted sHR was 1.37 (95%CI 
0.75 – 2.52). No statistical significant differences in the secondary outcomes were 
found. ConClusions: The early psychosocial intervention for patients with mild 
AD and their caregivers did not delay time to nursing home placement. The results 
of the present study are consistent with a recently published study (Waldorff et al. 
2012 BMJ) reporting no effect of semi-tailored intervention for patients with mild 
AD and their caregivers. Even if the present study did not manage to show differ-
ences between the study groups, it provides the valuable longitudinal dataset for 
studying long-term disease progression (in terms of correlated cognitive, behavioral, 
and functional disabilities) and its economic and quality of life consequences for 
patients with AD and their caregivers.
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objeCtives: To estimate the comparative efficacy of oral therapies (fingolimod, dime-
thyl fumarate [DMF] and teriflunomide) in delaying progression to disability health 
states in patients with relapsing–remitting multiple sclerosis (RRMS). Methods: Cox 
proportional hazards regression models were used to analyse 6-month confirmed 
disability progression (CDP; based on Expanded Disability Status Scale [EDSS] scores) 
in the pooled fingolimod FREEDOMS trials. Initial models were constructed with eight 
baseline covariates as main and treatment-interaction effects and final models with 
the most predictive covariates were selected using a stepwise algorithm. Models 
predicted hazard ratios (HRs) for 6-month CDP for fingolimod 0.5mg versus placebo 
for average TEMSO (teriflunomide trial) and pooled DEFINE/CONFIRM (DMF trials) 
patients. Time from EDSS score 0 to scores of 4 or 6 and to conversion to secondary 
progressive multiple sclerosis (SPMS) were estimated by fitting a multi-state Markov 
Transition model to individual patient data from the pooled FREEDOMS placebo 
groups (HRs accounted for treatment effects) and the London Ontario cohort (SPMS 
and RRMS–SPMS transitions). Results: Without covariate adjustment, the HR for 
CDP for fingolimod versus placebo in the pooled FREEDOMS trials was numerically 
lower (i.e. fingolimod more efficacious) than that for DMF twice daily versus placebo 
in DEFINE/CONFIRM (0.62 vs. 0.71). In adjusted comparisons, the predicted HR for 
fingolimod versus placebo in the DEFINE/CONFIRM population was lower than in the 
FREEDOMS population (initial model, 0.51; final model, 0.60). Fingolimod increased 
median time to disability health states (EDSS 4, 1.0 years; EDSS 6, 1.5 years) and SPMS 
(1.9 years) compared with DMF. Comparisons with teriflunomide also showed fingoli-
mod increased times to disability health states. ConClusions: Fingolimod is the 
only oral treatment that has demonstrated a significant effect on 6-month CDP in a 
clinical trial and our modeling approach suggests that progression to severe disability 
health states is delayed by fingolimod.
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objeCtives: To compare the efficacy of tobramycin powder for inhalation (TIP) rela-
tive to tobramycin inhalation solution containing 300 mg/5ml of tobramycin (TIS-T) 
and 300mg/4ml of tobramycin (TIS-B), aztreonam lysine inhalation solution (AZLI), 
colistimethate sodium solution (colistin) and colistin inhalation powder (colistin-
P) for cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosainfection, 
by updating a systematic literature review (SLR) and network meta-analysis (NMA) 
with recently published evidence. Methods: The updated SLR was conducted in 
Medline, Medline in Process, Embase and the Cochrane Library up to 2012. Individual 
study results were synthesized and indirectly compared with a Bayesian NMA. As 
some trials included naïve patients (previously not exposed to the treatment) in one 
arm, and previously exposed patients to the treatment in the other arm, the naïve 
and exposed arms were considered separate treatment-by-population groups in 
the network. Results: Three new trials were identified and analysed with eleven 
trials identified in the previous SLR. In naïve populations, TIP is expected to have 
similar efficacy as TIS-T, TIS-B, and AZLI (difference in % change in FEV1 predicted 
at week 4 respectively -1.97 (95% Credible Interval -11.84, 8.03), -2.38 (-12.71, 7.98), 
and 1.53 (-7.04, 10.00)). Compared to colistin-P, TIP is expected to have similar effi-
cacy, however the point estimate is in favour of TIP (11.36 (-1.75, 24.31)). In exposed 
populations, TIP is expected to have similar efficacy as TIS-T, TIS-B and colistin 
(respectively -0.78 (-7.65, 5.99), 0.01 (-10.42, 10.46), and -5.75 (-21.23, 9.89)). No data 
